Caribou Biosciences, Inc. Operating Lease, Payments
Caribou Biosciences, Inc. (CRBU) reported Operating Lease, Payments of $4.31 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-03-05
- Caribou Biosciences, Inc. operating lease, payments for the quarter ending 2024-12-31 was $898.00K, a 20.88% decline year-over-year.
- Caribou Biosciences, Inc. operating lease, payments for the quarter ending 2024-09-30 was $783.00K, a 45.27% increase year-over-year.
- Caribou Biosciences, Inc. operating lease, payments for the quarter ending 2024-06-30 was $1.13M, a 17.10% increase year-over-year.
- Caribou Biosciences, Inc. operating lease, payments for the quarter ending 2024-03-31 was $711.00K, a 34.95% decline year-over-year.
- Caribou Biosciences, Inc. operating lease, payments for fiscal 2025 was $4.31M, a 22.37% increase from fiscal 2024.
- Caribou Biosciences, Inc. operating lease, payments for fiscal 2024 was $3.52M, a 5.63% decline from fiscal 2023.
- Caribou Biosciences, Inc. operating lease, payments for fiscal 2023 was $3.73M, a 7.61% increase from fiscal 2022.
- Caribou Biosciences, Inc. operating lease, payments for fiscal 2022 was $3.47M, a 0.49% decline from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $4.31M 10-K · filed 2026-03-05 | |||
| 2024-12-31 | $898.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.68M derived: sum of 2 quarters · filed 2026-03-05 | $2.81M derived: sum of 3 quarters · filed 2026-03-05 | $3.52M 10-K · filed 2026-03-05 |
| 2024-09-30 | $783.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.91M derived: sum of 2 quarters · filed 2024-11-06 | $2.62M 10-Q · filed 2024-11-06 | $3.76M derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-06-30 | $1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.84M 10-Q · filed 2024-08-06 | $2.98M derived: sum of 3 quarters · filed 2025-03-10 | $3.52M derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-03-31 | $711.00K 10-Q · filed 2024-05-07 | $1.85M derived: sum of 2 quarters · filed 2025-03-10 | $2.38M derived: sum of 3 quarters · filed 2025-03-10 | $3.35M derived: sum of 4 quarters · filed 2025-03-10 |
| 2023-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $1.67M derived: sum of 2 quarters · filed 2025-03-10 | $2.64M derived: sum of 3 quarters · filed 2025-03-10 | $3.73M 10-K · filed 2025-03-10 |
| 2023-09-30 | $539.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.50M derived: sum of 2 quarters · filed 2024-11-06 | $2.60M 10-Q · filed 2024-11-06 | $3.61M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $965.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $2.06M 10-Q · filed 2024-08-06 | $3.07M derived: sum of 3 quarters · filed 2024-08-06 | $3.78M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $1.09M 10-Q · filed 2024-05-07 | $2.11M derived: sum of 2 quarters · filed 2024-05-07 | $2.82M derived: sum of 3 quarters · filed 2024-05-07 | $3.69M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $1.73M derived: sum of 2 quarters · filed 2024-03-11 | $2.60M derived: sum of 3 quarters · filed 2024-03-11 | $3.47M 10-K · filed 2024-03-11 |
| 2022-09-30 | $711.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $1.58M derived: sum of 2 quarters · filed 2023-11-07 | $2.45M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $872.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.74M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $871.00K 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $3.48M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |